BIOCON - Biocon Ltd. Share Price

In the Q4 FY26 earnings call, Biocon Limited management expressed a positive outlook for the upcoming fiscal year. The key focus is on execution, operating leverage, and value creation following the completion of significant strategic transitions and a major investment phase. They emphasized the completion of the integration of biosimilars and generics businesses within 100 days, which strengthens their operational model and synergies.

Management highlighted several important points:

1. Financial Performance:

   • Q4 FY26 saw a 10% year-on-year growth in operating revenue, driven primarily by a 12% increase in biosimilars and a 13% rise in generics.
   • EBITDA for Q4 was INR 1,073 crores with an EBITDA margin of 23%, a 29% increase when adjusted for prior-year one-time gains.
   • The reported net profit before exceptional items for Q4 was INR 179 crores. For FY26, net profit before exceptional items was INR 436 crores.

2. Future Growth:

   • The biosimilars segment is expected to sustain momentum with recent product approvals and U.S. commercial launches expected to ramp up in FY27.
   • Generics are anticipated to enhance profitability, particularly with new product stabilizations and improvements in utilization.

3. Deleveraging Focus:

   • The company aims to use free cash flow primarily for reducing net debt, which has declined from over $1.5 billion in March 2025 to between $1.1 billion and $1.2 billion.

4. Product Pipeline and Expansion:

   • Upcoming launches include Bosayaâ„¢ and Aukelsoâ„¢ in the U.S., with significant potential in diabetes and oncology markets.
   • Continued commitment to R&D, maintaining 7% of revenue from R&D investments, is expected to support future innovation and product development.

5. Operating Strategy:

   • Management emphasized transitioning focus from heavy investment to improving operational efficiency and maximizing returns on capital employed.

With these strategic initiatives, Biocon positions itself toward delivering consistent performance and sustained long-term value creation moving into FY27 and beyond.

Q&A Section Summary

Question 1: Neha Manpuria (Bank of America) - "Regarding biosimilars revenue, how should we think about FY '27 and FY '28, considering past disruptions?"

Answer: I noted a sequential growth of 12% in Q4 revenue compared to Q3. While we don't provide specific numbers for FY '27 and '28, we expect ramp-up from multiple launches, including Aspart. Our biosimilar ustekinumab is gaining traction, with a notable market share increase. Q4's growth lays the groundwork for continued progression as we move along FY '27.

Question 2: Neha Manpuria - "What is your deleveraging strategy for FY '27 now that Biocon Biologics merger is complete?"

Answer: Every dollar generated as free cash flow will primarily be used for debt reduction. Our net debt has decreased from over $1.5 billion in March '25 to about $1.1 billion now. We anticipate an ongoing focus on deleveraging, expecting substantial interest savings to accrue as well.

Question 3: Damayanti Kerai - "Can you provide a split of FY '26 sales between developed and emerging markets?"

Answer: Our sales typically split roughly 40% North America, 35% Europe, and 25% emerging markets. The aflibercept launch is significant, and while a competitor has gained market share, we are confident about our upcoming launch reflecting our established reputation.

Question 4: Damayanti Kerai - "What visibility do you have for the demand and supply of insulin Aspart?"

Answer: Insulin Aspart presents a significant opportunity. We currently hold 100% share in some closed networks in the U.S. As we approach market entry, we believe we can secure a considerable market portion and will keep you updated on our progress.

Question 5: Sanjay Kohli (Goldstone Capital) - "Can you clarify the INR760 crores under the comprehensive income?"

Answer: This figure relates to adjustments in other comprehensive income, which do not directly appear in normal P&L statements. I suggest discussing it offline for detailed clarification.

Question 6: Avnish Burman (Vaikarya) - "How will recent FDA guidelines affect Biocon's R&D costs?"

Answer: FDA's guidelines could halve our development costs and expedite time-to-market by 3-4 years. While it might seem the standards have lowered, they actually demand higher analytical comparability, which positions us favourably due to our expertise.

Question 7: Sidharth Negandhi (CWC) - "What are the growth numbers in constant currency for each division?"

Answer: For biosimilars, Q4's reported 12% growth translates to about 7% in constant currency. These trajectories suggest steady growth across the portfolio, with certain products beyond $200 million illustrating our solid market position.

Question 8: Tushar Manudhane (Motilal Oswal) - "What is your current capacity utilization and future needs?"

Answer: While capacity utilization varies, it remains healthy. We do not foresee the need for major new expansions, as our current and upcoming capacity in Malaysia will support growth adequately.

Please let me know if you would like to explore any particular aspect further!